Penumbra, Inc. has announced additional results from the STORM-PE randomized controlled trial evaluating the use of computer assisted vacuum thrombectomy (CAVT™) with anticoagulation in patients with acute intermediate-high risk pulmonary embolism (PE). According to the company, the STORM-PE trial demonstrated that CAVT combined with anticoagulation resulted in significantly greater improvements in thrombus burden reduction, heart rate, oxygen requirement, and functional outcomes compared to anticoagulation alone. These results were presented at the Vascular Interventional Advances (VIVA) 2025 Conference and published in the journal Circulation. The findings suggest that CAVT with anticoagulation may offer superior efficacy over anticoagulation alone for this patient population.